Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation.
Pignone
Michael
M
Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Alberts
Mark J
MJ
Colwell
John A
JA
Cushman
Mary
M
Inzucchi
Silvio E
SE
Mukherjee
Debabrata
D
Rosenson
Robert S
RS
Williams
Craig D
CD
Wilson
Peter W
PW
Kirkman
M Sue
MS
D000572:American Heart Association; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D048909:Diabetes Complications / Q000150:complications*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D012955:Societies, Medical; D014481:United States
D010975:Platelet Aggregation Inhibitors; D001241:Aspirin